Core Insights - The report by KPMG highlights that China's medical aesthetics industry has reached a market size of over 100 billion RMB and is experiencing the fastest growth globally, with potential to reach 1 trillion RMB by 2030 [1] Market Demand - In 2024, over 50% of the market demand for medical aesthetics will come from Generation Z (born 1997-2012), who view these services as a form of daily self-care rather than corrective treatments [1] - There is a rising demand from male consumers for light medical aesthetic procedures such as hyaluronic acid injections, botulinum toxin, microneedling, and intense pulsed light treatments [1] Market Growth - The market size for light medical aesthetics grew from 50.2 billion RMB in 2018 to 146 billion RMB in 2023, with the number of consumers increasing from 7.4 million to 23.5 million [1] - The shift towards non-surgical procedures is significant due to their lower risks, shorter recovery times, and easier accessibility [1] Geographic Trends - Medical aesthetic demand is shifting from traditional first-tier cities like Shanghai and Beijing to emerging first and second-tier cities such as Chengdu, Chongqing, and Hangzhou, which have lower living costs and considerable disposable income [1]

Group 1: Market Overview - The "beauty economy" in China has reached a scale of one trillion yuan, indicating significant consumer demand in the beauty and health sectors [1][6] - The aging population is driving the growth of the medical beauty industry, with a notable increase in demand for anti-aging and skin repair services among middle-aged and elderly consumers [6][8] Group 2: Industry Collaborations and Innovations - L'Oréal and Fudan University Huashan Hospital announced the establishment of a joint skin science laboratory to promote innovation in skin science through research and technology transfer [3] - L'Oréal released the first industry white paper on PDRN skincare applications, providing guidance for the development of skin science [4] Group 3: Consumer Trends and Product Development - The demand for beauty and health products among the elderly is comprehensive, prompting manufacturers to create practical and stylish products to meet the needs of the "new-age" consumers [7] - The introduction of smart hearing glasses by EssilorLuxottica aims to transform hearing aids into fashionable accessories, addressing aesthetic concerns for users [7] Group 4: Policy and Regulatory Environment - The National Medical Products Administration has streamlined approval processes, reducing clinical trial timelines, which fosters a more favorable environment for industry innovation [6] - The integration of healthcare and elderly care services is being promoted through collaborations, such as the partnership between Shanghai Kangyang Group and Ruijin Hospital [8]

Core Insights - The China medical beauty industry is rapidly rising, driven by a large market size, evolving technology, and increasing consumer demand, positioning it as a global focal point [3][4][9] - The industry is projected to reach a market size of 1 trillion RMB by 2030, with a significant shift in consumer demographics towards younger generations, particularly Generation Z [4][5][9] Market Overview - The medical beauty market in China has grown from 50.2 billion RMB in 2018 to 146 billion RMB in 2023, with the number of consumers increasing from 7.4 million to 23.5 million [5] - The demand for non-invasive procedures, such as botulinum toxin and hyaluronic acid fillers, is on the rise, particularly among younger consumers who view these treatments as part of their daily self-care routine [5][6] Consumer Demographics - Generation Z accounts for over 50% of the market demand for medical beauty services, contrasting with previous generations who viewed these services as corrective treatments [4][5] - There is a notable increase in male consumers seeking light medical beauty treatments, indicating a diversification of the consumer base [4] Growth Drivers - The growth of the medical beauty industry is supported by economic factors, with over 400 million middle-income individuals in urban areas and an aging population driving demand for anti-aging and skin repair services [6][7] - The industry is also benefiting from personalized service offerings and the adoption of advanced technologies, such as AI skin analysis tools [6] Geographic Trends - Demand for medical beauty services is expanding from traditional first-tier cities like Shanghai and Beijing to emerging second-tier cities such as Chengdu and Hangzhou, which offer lower living costs and substantial disposable income [7] Innovation and Challenges - Despite strong growth, the industry faces challenges such as safety compliance, talent shortages, and consumer retention [8] - Innovations in service models, including digital and remote consultations, are expected to drive future growth, alongside advancements in regenerative medicine [8] Future Outlook - The medical beauty industry in China is moving towards a more mature, regulated, and intelligent development phase, with opportunities for international collaboration and technology leadership [9] - The industry is anticipated to contribute to the "Healthy China 2030" strategy by enhancing domestic demand and injecting new growth momentum into the global beauty and health sector [9]

Core Insights - The report by KPMG highlights the rapid growth of China's medical aesthetics industry, with a market size of 3,115 billion yuan in 2023, projected to reach 13 trillion yuan by 2030 [1] - The industry is characterized by increasing consumer demand, particularly among younger demographics, and is reshaping the global medical aesthetics market [1] Group 1: Market Growth - China's medical aesthetics industry is one of the fastest-growing markets globally, driven by a large market size, evolving technologies, and rising consumer demand [1] - The middle-income group in urban areas has surpassed 400 million people, expected to reach 800 million in the next decade, contributing to the transformation of medical aesthetics from a luxury to an optional consumption [1] Group 2: Consumer Trends - There is a growing demand for non-invasive medical aesthetic services, particularly among emerging middle-aged and elderly consumers, which is becoming a significant supplement to industry growth [1] Group 3: Challenges and Innovations - Despite strong growth, the industry faces challenges such as safety compliance, talent shortages, and consumer outflow [2] - Innovations in medical aesthetics, including telemedicine and new business models, are shaping the future landscape of the industry [2] - Subscription-based beauty plans may emerge as a new business model, providing regular income for companies and enhancing customer loyalty [2] Group 4: Regional Expansion - With increasing demand for medical aesthetic services in Southeast Asia, Chinese medical aesthetic companies are expected to expand their operations into this market [2]

Core Viewpoint - Haohai Biological Technology has been actively repurchasing its shares, indicating a strategy to support its stock price amid declining performance metrics in the medical aesthetics sector [1][4]. Share Buyback Activity - The company spent HKD 805,700 to repurchase 29,600 shares on November 5, marking the third consecutive trading day of buybacks in November [1]. - In total, Haohai has conducted 23 share buybacks this year, with 11 in the first half and 12 in the second half [1]. - The share buybacks in the second half were divided into two phases: the first from September 15 to September 24, and the second from October 27 to November 5 [1]. Financial Performance - For Q3 2025, the company reported revenue of CNY 594 million, a year-on-year decline of 11.29%, and a net profit of CNY 93.58 million, down 11.39% [4]. - Year-to-date revenue for the first three quarters was CNY 1.899 billion, down 8.47%, with a net profit of CNY 305 million, a decrease of 10.63% [4]. - The decline in revenue is attributed to insufficient domestic consumer demand, intensified industry price competition, and tax rate adjustments [4]. Business Segment Performance - The medical aesthetics segment generated CNY 575 million, accounting for 44.35% of total revenue, with hyaluronic acid products contributing CNY 347 million, down 16.80% [5]. - The epidermal growth factor products saw revenue of CNY 92.38 million, reflecting a growth of 13.73% [5]. Market Position and Valuation - Haohai's current PE (TTM) ratio is 14.82, below the industry average of 20, indicating potential undervaluation [3]. - Despite the stock price decline, the company maintains a net asset value of HKD 26.93 per share, providing an arbitrage opportunity for investors [7]. - Since August 20, 2023, the proportion of shares held by Hong Kong Stock Connect investors has increased from 30.35% to 35.78% [7]. Strategic Focus on Botulinum Toxin - The company has invested USD 31 million in Eirion to develop various botulinum toxin products, aiming to capture a share of the growing market [9]. - The medical aesthetics injection market is dominated by hyaluronic acid and botulinum toxin, which together account for 65% of the market [10]. - The domestic penetration rate for botulinum toxin is significantly lower than in mature markets, suggesting substantial growth potential [12]. Future Outlook - Despite current performance challenges, the company's ongoing development in the botulinum toxin sector may provide a pathway for recovery [14]. - The collaboration with Eirion is expected to yield new products that could enhance market presence and profitability in the future [14].

Core Viewpoint - Haohai Biological Technology has been actively repurchasing its shares, indicating a strategy to support its stock price amid declining performance metrics in the medical aesthetics sector [1][4]. Share Buyback Activity - The company spent HKD 805,700 to repurchase 29,600 shares on November 5, marking the third consecutive trading day of buybacks in November [1]. - In total, Haohai has conducted 23 share buybacks this year, with 11 in the first half and 12 in the second half [1]. - The second phase of buybacks occurred from October 27 to November 5, following an initial phase from September 15 to September 24 [1]. Financial Performance - For Q3 2025, the company reported revenue of CNY 594 million, a year-on-year decline of 11.29%, and a net profit of CNY 93.58 million, down 11.39% [4]. - Year-to-date revenue for the first three quarters was CNY 1.899 billion, down 8.47%, with net profit decreasing by 10.63% to CNY 305 million [4]. - The decline in revenue is attributed to insufficient domestic consumer demand, intensified industry price competition, and tax rate adjustments [4]. Business Segment Analysis - The medical aesthetics segment generated CNY 575 million in revenue, accounting for 44.35% of total revenue, with hyaluronic acid products contributing CNY 347 million, down 16.80% [4][6]. - The epidermal growth factor products saw a revenue increase of 13.73% to CNY 92.38 million [4][6]. Market Position and Valuation - Haohai's current PE (TTM) ratio stands at 14.82, below the industry average of 20 [3]. - Despite the declining stock price, the company maintains a net asset value of HKD 26.93 per share, providing potential profit opportunities for investors [8]. Strategic Focus on Botulinum Toxin - The company has entered a partnership with Eirion to develop botulinum toxin products, aiming to capture a share of the growing market [10][15]. - The botulinum toxin market is dominated by foreign brands, but there is significant room for growth in China, where the penetration rate is currently low compared to mature markets like the U.S. [12][13]. Industry Trends - The medical aesthetics market is experiencing a shift, with hyaluronic acid and botulinum toxin being the leading materials, comprising 98% of the injection market [10]. - The domestic market for collagen is growing rapidly, with a projected compound annual growth rate of 41.45% from 2023 to 2027 [11].

Core Viewpoint - The Hong Kong IPO market has been thriving since 2025, with expectations to maintain its leading position in the global new stock financing market due to attractive listing systems, broad industry coverage, and ample liquidity [1][7]. Summary by Sections IPO Market Performance - In the first ten months of this year, the total IPO fundraising in Hong Kong reached HKD 215.46 billion (approximately USD 27.72 billion), significantly exceeding the initial annual fundraising expectation of USD 17-20 billion [2]. - The improvement in liquidity and the rapid decline in Hong Kong dollar interest rates have lowered borrowing costs, enhancing investor enthusiasm for new listings [2]. Characteristics of the Current IPO Wave - A+H listing model has become mainstream, with over 50% of new companies having overseas operations, accounting for 80% of the fundraising amount [3]. - The "technology + consumption" dual-drive model is evident, with the consumer sector dominating IPOs, particularly in emerging consumption and service-oriented segments [3]. - New IPOs have shown significantly better performance compared to the average of the past five years, with an average return of approximately 38% on the first trading day and 60% after three months [3]. Investor Sentiment and Market Dynamics - The new stock breaking rate has dropped to a new low, with many newly listed companies experiencing minimal price discounts, which may encourage more companies to consider listing [4]. - Investors are increasingly focusing on future growth potential and cornerstone shareholder ratios rather than just company size when considering new listings [4]. Foreign Investment Trends - Global investors have actively participated in the Hong Kong IPO market, with cornerstone investments and institutional placements seeing significant involvement from international institutions [6]. - Passive foreign capital has maintained a net inflow trend, while active foreign capital is expected to increase due to the attractive performance of new stocks [6]. Regulatory and Market Environment - The Hong Kong Stock Exchange has implemented several reforms since 2018 to optimize the listing process, significantly improving listing efficiency [7]. - The number of companies preparing for IPOs has increased to nearly 300, surpassing the previous peak of about 200 in August 2021, indicating a robust pipeline for future listings [7]. Return of Chinese Companies - The return of Chinese companies listed in the U.S. to Hong Kong is anticipated to provide new growth in the IPO market, driven by ongoing U.S.-China trade tensions [8][9].

Market Overview - Major indices opened higher with Shanghai Composite Index up 0.10%, Shenzhen Component Index up 0.37%, and ChiNext Index up 0.60% [1] - The storage, HBM, and power grid sectors showed significant gains [1] Index Performance - Shanghai Composite Index: 3973.35, up 0.10%, with a trading volume of 83.35 billion [2] - Shenzhen Component Index: 13272.47, up 0.37%, with a trading volume of 101.14 billion [2] - ChiNext Index: 3185.13, up 0.60%, with a trading volume of 41.02 billion [2] External Market Influences - U.S. stock indices experienced slight gains, with S&P 500 up 0.37%, Nasdaq up 0.65%, and Dow Jones up 0.48% [3] - Chinese concept stocks rebounded, with notable performances from Alibaba, JD.com, and NIO, while Pinduoduo and others also showed mixed results [3] Sector Insights - Citic Securities anticipates multiple factors will likely drive gold prices upward, influenced by geopolitical tensions and U.S. economic performance [4] - CITIC Construction believes the medical device sector is at a turning point, with opportunities for valuation and performance recovery, especially in respiratory testing and home device sales [5] - China Merchants Securities highlights strong performance in the securities industry, with a year-on-year increase in revenue and net profit for listed brokerages [6] - CICC is optimistic about the recovery in the restaurant and tourism sectors, expecting policy expansion to boost demand [7][8]

Core Viewpoint - The light industry retail beauty sector is experiencing a weak recovery since 2025, with significant differentiation among sub-sectors and companies due to varying attributes and policy sensitivities. Domestic demand remains weak, while certain segments like trendy toys and beauty products show growth. International trade policies are slowing export growth. Looking ahead to 2026, government policies are expected to support consumption stabilization, but the marginal effects may diminish, leading to differentiated growth across sub-sectors [3]. Beauty and Aesthetic Medicine - The beauty sector is projected to achieve mid-single-digit growth in 2026, driven by domestic demand recovery. Ingredient upgrades and product innovations, particularly with emerging components like collagen and PDRN, are expected to enhance consumer purchasing needs. Competition is intensifying, leading to a concentration of market share among leading brands. The industry is anticipated to exhibit three trends: 1) National brands are moving towards globalization and group development; 2) Channel efficiency and operational capabilities are becoming more critical; 3) Market share is increasingly concentrated among top-performing brands [6]. - The aesthetic medicine sector is expected to see double-digit growth in 2026, supported by increased penetration rates and continuous market education. The supply side is becoming richer, stimulating demand. Two key trends are anticipated: 1) Midstream institutions are focusing on premium products and marketing capabilities; 2) Leading institutions are expanding through enhanced user operations and solutions [7]. Personal Care - The personal care sector is expected to benefit from increased online penetration and the rise of self-care demands, leading to a restructuring of the market. Product structures are anticipated to upgrade towards efficacy and premiumization. The rise of content e-commerce platforms is reshaping consumer access and marketing, providing opportunities for domestic brands to gain market share, particularly in segments like baby care, women's hygiene, and oral care [8]. Commercial New Retail - The retail sector is expected to continue its steady recovery into 2026, characterized by three trends: 1) Consumers are increasingly valuing cost-performance ratios, prompting businesses to focus on differentiated product offerings; 2) The clearance of outdated retail formats is nearing completion, with improved operational efficiency leading to profitability; 3) New consumption trends driven by emotional value are creating demand, supported by innovative product categories and localized operations [10]. Light Industry Manufacturing - The light manufacturing sector is facing weak overall demand but presents structural opportunities. Companies that can leverage industry transformation to develop new business models are expected to thrive. Key opportunities include: 1) Industry transformation driven by technological advancements, particularly in AI applications; 2) Export opportunities as companies enhance resilience through diversified global production and capitalize on improving overseas demand [13][14].

Group 1 - The core viewpoint of the article highlights that the terminal prices of the company's products are influenced by multiple factors, including downstream channel competition and consumer demand [1] - For the period from January to September 2025, the company's comprehensive gross profit margin is reported at 93.36%, a decrease from 94.80% in the same period last year [1] - The company's ex-factory prices have remained relatively stable despite the changes in gross profit margin [1]